Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Masliah, E.
Right arrow Articles by Morris, J.C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Masliah, E.
Right arrow Articles by Morris, J.C.
Related Collections
Right arrow Alzheimer's disease

Altered expression of synaptic proteins occurs early during progression of Alzheimer’s disease

E. Masliah, MD;, M. Mallory, BS;, M. Alford, BS;, R. DeTeresa, BS;, L.A. Hansen, MD;, D.W. McKeel, Jr., MD; and J.C. Morris, MD

From the Departments of Neurosciences (Drs. Masliah and Hansen, M. Mallory, M. Alford, and R. DeTeresa) and Pathology (Drs. Masliah and Hansen), School of Medicine, University of California, San Diego, La Jolla; and Departments of Neurology (Dr. Morris) and Pathology (Drs. McKeel and Morris), Washington University School of Medicine, St. Louis, MO.



View larger version (27K):

[in a new window]
  		Figure. Dot-blot analysis of the control and AD frontal cortex. (A) Compared with control cases, mild AD cases showed a 25% loss in synaptophysin immunoreactivity. Levels of synaptophysin were further decreased in both moderate and severe cases. (B) Whereas there was no difference in levels of synaptotagmin between control and mild AD cases, there was a significant reduction in levels of immunoreactivity in moderate and severe AD. (C) Levels of growth-associated protein 43 (GAP43) were unchanged in mild AD cases compared with control subjects. In contrast, mild and moderate cases showed a significant and progressive reduction in levels of GAP43 immunoreactivity. *Indicates p < 0.05 (one-way analysis of variance with post hoc Dunnet’s test).

 




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2001 by AAN Enterprises, Inc.